
Corey S Davis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5400532/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Opioid-overdose laws association with opioid use and overdose mortality. Addictive Behaviors, 2018, 86, 90-95.	1.7	164
2	Today's fentanyl crisis: Prohibition's Iron Law, revisited. International Journal of Drug Policy, 2017, 46, 156-159.	1.6	156
3	Association between medical cannabis laws and opioid overdose mortality has reversed over time. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 12624-12626.	3.3	154
4	Laws limiting the prescribing or dispensing of opioids for acute pain in the United States: A national systematic legal review. Drug and Alcohol Dependence, 2019, 194, 166-172.	1.6	143
5	Legal changes to increase access to naloxone for opioid overdose reversal in the United States. Drug and Alcohol Dependence, 2015, 157, 112-120.	1.6	135
6	Expanded Access to Naloxone Among Firefighters, Police Officers, and Emergency Medical Technicians in Massachusetts. American Journal of Public Health, 2014, 104, e7-e9.	1.5	125
7	Effects of an Intensive Street-Level Police Intervention on Syringe Exchange Program Use in Philadelphia, Pa. American Journal of Public Health, 2005, 95, 233-236.	1.5	123
8	State legal innovations to encourage naloxone dispensing. Journal of the American Pharmacists Association: JAPhA, 2017, 57, S180-S184.	0.7	114
9	State naloxone access laws are associated with an increase in the number of naloxone prescriptions dispensed in retail pharmacies. Drug and Alcohol Dependence, 2018, 189, 37-41.	1.6	97
10	Orienting patients to greater opioid safety: models of community pharmacy-based naloxone. Harm Reduction Journal, 2015, 12, 25.	1.3	90
11	Continuing increased access to buprenorphine in the United States via telemedicine after COVID-19. International Journal of Drug Policy, 2021, 93, 102905.	1.6	74
12	Emergency Medical Services Naloxone Access: A National Systematic Legal Review. Academic Emergency Medicine, 2014, 21, 1173-1177.	0.8	73
13	Physician continuing education to reduce opioid misuse, abuse, and overdose: Many opportunities, few requirements. Drug and Alcohol Dependence, 2016, 163, 100-107.	1.6	69
14	Opioid Policy Changes During the COVID-19 Pandemic - and Beyond. Journal of Addiction Medicine, 2020, 14, e4-e5.	1.4	68
15	Association of Medicaid Expansion With Opioid Overdose Mortality in the United States. JAMA Network Open, 2020, 3, e1919066.	2.8	65
16	Engaging Law Enforcement in Overdose Reversal Initiatives: Authorization and Liability for Naloxone Administration. American Journal of Public Health, 2015, 105, 1530-1537.	1.5	59
17	Prescribe to Prevent: Overdose Prevention and Naloxone Rescue Kits for Prescribers and Pharmacists. Journal of Addiction Medicine, 2016, 10, 300-308.	1.4	57
18	Changing Law from Barrier to Facilitator of Opioid Overdose Prevention. Journal of Law, Medicine and Ethics, 2013, 41, 33-36.	0.4	56

#	Article	IF	CITATIONS
19	Laws Mandating Coprescription of Naloxone and Their Impact on Naloxone Prescription in Five US States, 2014–2018. American Journal of Public Health, 2020, 110, 881-887.	1.5	56
20	Systematic review of the emerging literature on the effectiveness of naloxone access laws in the United States. Addiction, 2021, 116, 6-17.	1.7	56
21	Do naloxone access laws increase outpatient naloxone prescriptions? Evidence from Medicaid. Drug and Alcohol Dependence, 2018, 190, 37-41.	1.6	54
22	Naloxone laws facilitate the establishment of overdose education and naloxone distribution programs in the United States. Drug and Alcohol Dependence, 2018, 188, 370-376.	1.6	52
23	The Law (and Politics) of Safe Injection Facilities in the United States. American Journal of Public Health, 2008, 98, 231-237.	1.5	50
24	Rise and regional disparities in buprenorphine utilization in the United States. Pharmacoepidemiology and Drug Safety, 2020, 29, 708-715.	0.9	49
25	Evolution and Convergence of State Laws Governing Controlled Substance Prescription Monitoring Programs, 1998-2011. American Journal of Public Health, 2014, 104, 1389-1395.	1.5	48
26	Bundling occupational safety with harm reduction information as a feasible method for improving police receptiveness to syringe access programs: evidence from three U.S. cities. Harm Reduction Journal, 2009, 6, 16.	1.3	46
27	Prescription drug monitoring programs operational characteristics and fatal heroin poisoning. International Journal of Drug Policy, 2019, 74, 174-180.	1.6	44
28	Harmonizing disease prevention and police practice in the implementation of HIV prevention programs: Up-stream strategies from Wilmington, Delaware. Harm Reduction Journal, 2012, 9, 17.	1.3	40
29	Prescription drug monitoring program design and function: A qualitative analysis. Drug and Alcohol Dependence, 2017, 180, 395-400.	1.6	40
30	Measuring Relationships Between Proactive Reporting State-level Prescription Drug Monitoring Programs and County-level Fatal Prescription Opioid Overdoses. Epidemiology, 2020, 31, 32-42.	1.2	40
31	Laws limiting prescribing and dispensing of opioids in the United States, 1989–2019. Addiction, 2021, 116, 1817-1827.	1.7	40
32	Using telehealth to improve buprenorphine access during and after COVID-19: A rapid response initiative in Rhode Island. Journal of Substance Abuse Treatment, 2021, 124, 108283.	1.5	40
33	Opioid Prescribing Laws Are Not Associated with Short-term Declines in Prescription Opioid Distribution. Pain Medicine, 2020, 21, 532-537.	0.9	39
34	Patient perspectives on an opioid overdose education and naloxone distribution program in the U.S. Department of Veterans Affairs. Substance Abuse, 2016, 37, 118-126.	1.1	34
35	Legal and policy changes urgently needed to increase access to opioid agonist therapy in the United States. International Journal of Drug Policy, 2019, 73, 42-48.	1.6	34
36	From Peers to Lay Bystanders: Findings from a Decade of Naloxone Distribution in Pittsburgh, PA. Journal of Psychoactive Drugs, 2018, 50, 240-246.	1.0	33

#	Article	IF	CITATIONS
37	The SUPPORT for Patients and Communities Act — What Will It Mean for the Opioid-Overdose Crisis?. New England Journal of Medicine, 2019, 380, 3-5.	13.9	27
38	A typology of prescription drug monitoring programs: a latent transition analysis of the evolution of programs from 1999 to 2016. Addiction, 2019, 114, 248-258.	1.7	26
39	Legality of drug checking equipment in the United States: A systematic legal analysis. Drug and Alcohol Dependence, 2022, 234, 109425.	1.6	25
40	Medical Providers' Knowledge and Concerns about Opioid Overdose Education and Take-Home Naloxone Rescue Kits within Veterans Affairs Health Care Medical Treatment Settings. Substance Abuse, 2017, 38, 135-140.	1.1	24
41	Paraphernalia Laws, Criminalizing Possession and Distribution of Items Used to Consume Illicit Drugs, and Injection-Related Harm. American Journal of Public Health, 2019, 109, 1564-1567.	1.5	24
42	Co-Prescribing Naloxone does not Increase Liability Risk. Substance Abuse, 2016, 37, 498-500.	1.1	23
43	Attitudes of North Carolina law enforcement officers toward syringe decriminalization. Drug and Alcohol Dependence, 2014, 144, 265-269.	1.6	22
44	Over the counter naloxone needed to save lives in the United States. Preventive Medicine, 2020, 130, 105932.	1.6	22
45	Good Samaritan laws and overdose mortality in the United States in the fentanyl era. International Journal of Drug Policy, 2021, 97, 103294.	1.6	22
46	Overdose Epidemic, Prescription Monitoring Programs, and Public Health: A Review of State Laws. American Journal of Public Health, 2015, 105, e9-e11.	1.5	21
47	Perceived Unintended Consequences of Prescription Drug Monitoring Programs. Substance Use and Misuse, 2019, 54, 345-349.	0.7	21
48	The importance of data source in prescription drug monitoring program research. Health Services Research, 2021, 56, 268-274.	1.0	21
49	Considering the Potential Benefits of Over-the-Counter Naloxone. Integrated Pharmacy Research & Practice, 2021, Volume 10, 13-21.	0.9	20
50	Lessons Learned from the Expansion of Naloxone Access in Massachusetts and North Carolina. Journal of Law, Medicine and Ethics, 2015, 43, 19-22.	0.4	19
51	Discrepancies in addressing overdose prevention through prescription monitoring programs. Drug and Alcohol Dependence, 2015, 153, 355-358.	1.6	13
52	Addressing the overdose epidemic requires timely access to data to guide interventions. Drug and Alcohol Review, 2016, 35, 383-386.	1.1	13
53	Action, Not Rhetoric, Needed to Reverse the Opioid Overdose Epidemic. Journal of Law, Medicine and Ethics, 2017, 45, 20-23.	0.4	13
54	Regional and temporal effects of naloxone access laws on opioid overdose mortality. Substance Abuse, 2020, 42, 1-10.	1.1	13

#	Article	IF	CITATIONS
55	The Law and Policy of Opioids for Pain Management, Addiction Treatment, and Overdose Reversal. Indiana Health Law Review, 2017, 14, 1.	0.1	13
56	Toward Healthy Drug Policy in the United States — The Case of Safehouse. New England Journal of Medicine, 2020, 382, 4-5.	13.9	12
57	Assessing Social Risks Prior to Commencement of a Clinical Trial: Due Diligence or Ethical Inflation?. American Journal of Bioethics, 2009, 9, 48-54.	0.5	10
58	Self-Regulating Profession? Administrative Discipline of "Pill Mill―Physicians in Florida. Substance Abuse, 2017, 38, 265-268.	1.1	10
59	Harm Reduction, By Mail: the Next Step in Promoting the Health of People Who Use Drugs. Journal of Urban Health, 2021, 98, 532-537.	1.8	10
60	Commentary on Pardo (2017) and Moyo <i>et al.</i> (2017): Much still unknown about prescription drug monitoring programs. Addiction, 2017, 112, 1797-1798.	1.7	8
61	Reducing Harm Through Litigation Against Opioid Manufacturers? Lessons From the Tobacco Wars. Public Health Reports, 2018, 133, 207-213.	1.3	8
62	Expanding Mail-Based Distribution of Drug-Related Harm Reduction Supplies Amid COVID-19 and Beyond. American Journal of Public Health, 2021, 111, 1013-1017.	1.5	8
63	Spatiotemporal Analysis of the Association Between Pain Management Clinic Laws and Opioid Prescribing and Overdose Deaths. American Journal of Epidemiology, 2021, 190, 2592-2603.	1.6	8
64	Will Emergency Holds Reduce Opioid Overdose Deaths?. New England Journal of Medicine, 2019, 381, 1795-1797.	13.9	6
65	Prescription Opioid Laws and Opioid Dispensing in US Counties. Epidemiology, 2021, 32, 868-876.	1.2	6
66	Reducing Opioid Overdose Deaths by Expanding Naloxone Distribution and Addressing Structural Barriers to Care. American Journal of Public Health, 2021, 111, 1382-1384.	1.5	6
67	The Purdue Pharma Opioid Settlement — Accountability, or Just the Cost of Doing Business?. New England Journal of Medicine, 2021, 384, 97-99.	13.9	6
68	Major Trends in Public Health Law and Practice: A Network National Report. Journal of Law, Medicine and Ethics, 2013, 41, 737-745.	0.4	4
69	Evidence-Based Policy Versus Morality Policy: The Case of Syringe Access Programs. Journal of Evidence-informed Social Work, 2015, 12, 425-437.	0.8	4
70	Naloxone affordability measures needed. Journal of the American Pharmacists Association: JAPhA, 2017, 57, 740-741.	0.7	4
71	Status of US State Laws Mandating Timely Reporting of Nonfatal Overdose. American Journal of Public Health, 2018, 108, 1159-1161.	1.5	4
72	State Approaches to Addressing the Overdose Epidemic: Public Health Focus Needed. Journal of Law, Medicine and Ethics, 2019, 47, 43-46.	0.4	4

#	Article	IF	CITATIONS
73	Legal Authority for Emergency Medical Services to Increase Access to Buprenorphine Treatment for Opioid Use Disorder. Annals of Emergency Medicine, 2021, 78, 102-108.	0.3	4
74	Legal Innovations to Advance a Culture of Health. Journal of Law, Medicine and Ethics, 2015, 43, 904-912.	0.4	3
75	Intranasal Naloxone for Opioid Overdose Reversal. Prehospital Emergency Care, 2015, 19, 135-137.	1.0	3
76	Opportunities to Improve Decision-Making About Opioid Prescribing. Journal of General Internal Medicine, 2017, 32, 3-5.	1.3	3
77	The Importance of Federal Action Supporting Overdose-Prevention Centers. New England Journal of Medicine, 2022, 386, 1965-1967.	13.9	2
78	A Modest Proposal. American Journal of Bioethics, 2009, 9, W3-W4.	0.5	1
79	National Health Care Reform and the Public's Health. Journal of Law, Medicine and Ethics, 2011, 39, 65-68.	0.4	1
80	Comments on Strang <i>et al</i> . (2016): †Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures?'. Addiction, 2016, 111, 1879-1880.	1.7	1
81	Bias Against People Who Inject Drugs Undermines Police Training on Needlestick Injury. American Journal of Public Health, 2019, 109, 839-840.	1.5	1
82	Davis et al. Respond. American Journal of Public Health, 2019, 109, e11-e12.	1.5	1
83	Laws Forbidding Pregnancy Discrimination in Substance Use Disorder Treatment Are Not Associated With Treatment Access. Journal of Addiction Medicine, 2021, Publish Ahead of Print, .	1.4	1
84	Letter to the Editor. Journal of Law, Medicine and Ethics, 2018, 46, 811-812.	0.4	0
85	Commentary on Neale et al . (2019): Foregrounding the competency, expertise and rights of people who use drugs. Addiction, 2019, 114, 719-720.	1.7	0
86	Opioid Litigation and Maternal-Child Health—Investing in the Future. JAMA Pediatrics, 2020, 174, 119.	3.3	0
87	Reply to Letter to the Editor Regarding Article: "Considering the Potential Benefits of Over-The-Counter Naloxone―[Response To Letter]. Integrated Pharmacy Research & Practice, 2021, Volume 10, 77-78	0.9	Ο